There were hopes that the drug Rituxin might benefit multiple sclerosis patients with the primary progressive stage of the disease, but a long term study of the therapy failed to produce a significant benefit.
Your email is never published nor shared. Required fields are marked *
You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
Rituxin Disappoints
There were hopes that the drug Rituxin might benefit multiple sclerosis patients with the primary progressive stage of the disease, but a long term study of the therapy failed to produce a significant benefit.